Instadose Pharma Corp. (OTCMKTS: INSD) Starts This Week After A +72% Run Last Week, Skyrocketing To $47.25 Friday

Can Instadose Pharma Corp. (OTCMKTS: INSD) this week top last week’s +72% run to $47.25 Friday from $27.45 Monday?

Instadose Canada made news for INSD as it continued signing and negotiating more JV partnerships to expand its Global Distribution Platform. INSD closed green all week.

It signed another international strategic joint venture agreement. This time it is with Sanctum Healthcare Remedies Private Limited, its India JV Partner. In turn, Sanctum agrees to grow, cultivate and sell Medicinal Cannabis and Cannabinoid Oil to Europe. It will market to Europe through INSD’s ‘Global Distribution Platform,’ INSD said. 

The signing is the latest in a series of similar JV partnerships signed by INSD with international partners. Earlier it signed a JV Partnership Agreement with Columbia JV Partners. INSD’s catalyst is its expanding global footprint for growing and distributing medical cannabis and cannabinoid oil.

And now Egypt could be next. It disclosed talks with Egypt’s government at the Arab African Investment Conference in a Tweet last week.

INSD’s growing, cultivating and marketing footprint worldwide is growing almost daily. On Friday, its stock rose again by 14.55% to $47.25 — culminating a one week +72% run. Trading was heavy again, almost five times its daily average.

In September it was $5 a share. Before its reverse merger on September 24, it was a shell company with no operations.

Grant Sanders, Chairman of Instadose, calls its JV international joint ventures strategic. They give Instadose open air cultivating land mass. They also add to INSD’s network of established marketing locations. Already, the Global Distribution Platform touches five continents including North and South America, Europe’s EU, India/Asia and South Africa/Congo. 

“Our partnership in India is a strategic pillar to Instadose’s Global Distribution Platform as Indian states such as Uttarakhand legalize Medical Cannabis,” Grant Sanders said. “With a population of approximately 1.4 billion and a growing middle class, the potential for Medicinal Cannabis in India is substantial.”

And now Instadose is eyeing a future JV partnership in the Middle East. As news broke about INSD attending a Conference and discussing a partnership with Egypt.

INSD is becoming a force in worldwide medicinal cannabis. From multiple growing and cultivation sites it is distributing to pharmaceutical firms globally. And it is negotiating for more.

INSD entered international joint venture agreements with India, Portuguese Republic and Columbia, Mexico

It is competing in a large worldwide market. The global medicinal cannabis market is anticipated to reach $46.18 billion by 2026 at a CAGR of 22.9% from 2021, according to research by Market Data Forecast. It also distributes cannabinoid oil worldwide.

Instadose Pharma Corp. (OTC MKTS: INSD) is seeking to create a large, outdoor growing, cultivation and global distribution program for its Medicinal Cannabis and Cannabinoid Oil. It would, through its Global Distribution Platform,  gain global access to a new wholesale market worldwide. 

This wholesale marketplace would then offer low-cost product as a bulk and active pharmaceutical ingredient. It would be large, sustainable, consistent, diverse and high quality.  

INSD Chairman Grant Sanders said, “The commoditization of Cannabis will have a huge impact on countries where it can be grown outdoors, particularly in the developing world. The hope is that these countries will benefit from the development of a global market for Medicinal Cannabis.”

INSD’s Global Distribution Platform is also focused on sustainable and long-term agreements. The goal is to give back to national people and the environment. Instadose aims to increase fresh water, jobs, education, food, quality of life and security.

INSD is focused on its three growing and cultivation centers in: Democratic Republic of the Congo (DRC), South Africa and Mexico.

This article is part of a sponsored investor education program.